Acetamides

BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021
Branches of biology, Neuraminidase inhibitors, Chemistry, Life sciences, Carbohydrate chemistry, BioCryst Pharmaceuticals, Acetamides, Guanidines, Peramivir, Neuraminidase, Viral neuraminidase, Influenza

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the Companys website at www.biocryst.com.

Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health

Retrieved on: 
Tuesday, December 22, 2020
Life sciences, Phthalimides, Health sciences, Health, Acetamides, Amgen, Apremilast, Tropical diseases, Celgene, Neglected tropical diseases, Global health

Amgen had acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla(apremilast) from Celgene in 2019.

Key Points: 
  • Amgen had acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla(apremilast) from Celgene in 2019.
  • Under the terms of the agreement, MDGH will assume full responsibility for the further development and commercialization of AMG 634.
  • "MDGH's track record and experience in product development, global health, and neglected infectious diseases makes them an ideal company to further develop AMG 634 for the benefit of patients."
  • "MDGH is dedicated to developing and delivering medicines for diseases that disproportionally affect people in low- and middle-income countries.

Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy

Retrieved on: 
Tuesday, December 15, 2020
Biopesticides, Polysaccharides, Health sciences, Life sciences, Chemistry, Acetamides, Biomolecules, Chitin, Chitosan, National Institutes of Health, Small Business Innovation Research, Therapy

The grant builds on Karamedicas nose-to-brain delivery system that was validated in the Phase I SBIR proof-of-concept studies using mouse models of CAA.

Key Points: 
  • The grant builds on Karamedicas nose-to-brain delivery system that was validated in the Phase I SBIR proof-of-concept studies using mouse models of CAA.
  • Karamedicas CAA therapy consists of smart microparticles made from chitosan, which is derived from chitin, a biopolymer obtained commercially from crustacean shells.
  • We made great strides in the Phase I with support of NIH and our collaborators, said Wolff Kirsch, MD, Karamedica Chairman & CEO.
  • We truly believe this therapy will revolutionize treatment of this terrible disease while also enabling therapies for other neurological disorders.

BioCryst to Present at JMP Securities Hematology Summit

Retrieved on: 
Friday, December 11, 2020
Branches of biology, Neuraminidase inhibitors, Chemistry, Life sciences, Carbohydrate chemistry, BioCryst Pharmaceuticals, Acetamides, Guanidines, Peramivir, Neuraminidase, Viral neuraminidase, Small molecule

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCrysts first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the Companys website at www.biocryst.com .

BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement

Retrieved on: 
Sunday, December 6, 2020
Acquired hemolytic anemia, Acetamides

In the study, BCX9930 was highly specific for the alternative pathway and, after oral dosing of BCX9930 in primates, alternative pathway activity was completely suppressed.

Key Points: 
  • In the study, BCX9930 was highly specific for the alternative pathway and, after oral dosing of BCX9930 in primates, alternative pathway activity was completely suppressed.
  • These data demonstrate that BCX9930 is a highly potent and specific orally bioavailable Factor D inhibitor with potential for treatment of patients with PNH and other alternative pathway mediated diseases, said Dr. William Sheridan, chief medical officer of BioCryst.
  • Discovered by BioCryst, BCX9930 is a novel, oral, potent and selective small molecule inhibitor of FactorD currently in Phase 1 clinical development for the treatment of complement-mediated diseases.
  • As a Factor D inhibitor, BCX9930 is designed as an oral monotherapy that can address both intravascular and extravascular hemolysis in PNH patients.

Global Tetraacetylethylenediamine (TAED) Market Report 2020: Historical Years 2015-2018 / Base Year 2019 / Estimated Year 2020 / Forecast Period 2021-2025

Retrieved on: 
Wednesday, October 14, 2020
Acetamides, Tetraacetylethylenediamine, Financial market

Increasing development of washing products is leading to increased use of TAED, which is a major factor boosting the growth of tetraacetylethylenediamine market.

Key Points: 
  • Increasing development of washing products is leading to increased use of TAED, which is a major factor boosting the growth of tetraacetylethylenediamine market.
  • Moreover, tetraacetylethylenediamine is biodegradable in nature with less environmental impacts, which is another key factor fuelling the growth of the Global TAED Market across the globe.
  • However, instability in the price of raw materials might hamper the growth of the Global Tetraacetylethylenediamine Market in the years to come.
  • The companies operating in tetraacetylethylenediamine market across the globe are focussing more towards expanding their share in the market.

Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis

Retrieved on: 
Tuesday, October 6, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Organ systems, Phthalimides, Autoimmune diseases, Acetamides, Amgen, Apremilast, Psoriasis, Medical specialties, Piclidenoson, Can-Fite BioPharma Ltd.

A separate IDMC for the interim analysis of the Acrobat Rheumatoid Arthritis Phase III study recommended not to continue this study.

Key Points: 
  • A separate IDMC for the interim analysis of the Acrobat Rheumatoid Arthritis Phase III study recommended not to continue this study.
  • Can-Fites Comfort Phase III psoriasis study is designed to establish Piclidenosons superiority compared to placebo and non-inferiority compared to Apremilast (Otezla) in patients with moderate to severe plaque psoriasis.
  • While the interim analysis data continue to be blinded to Can-Fite, and the results have only been available to the IDMC, their recommendation to continue the Phase III psoriasis study and also to drop one of the dosing groups are highly encouraging.
  • We thank the members of both of the IDMCs for their diligence in reviewing our Phase III interim data and for making their recommendations.

TaiGen filed US IND for its influenza antiviral TG-1000

Retrieved on: 
Sunday, October 4, 2020
RTT, Animal virology, Health, Medicine, Veterinary medicine, Acetamides, Neuraminidase inhibitors, Oseltamivir, Influenza A virus, Influenza, Avian influenza, Antiviral drug

TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.

Key Points: 
  • TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.
  • TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.
  • The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.
  • TaiGen Biotechnology is a leading research-based and market-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China.

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

Retrieved on: 
Saturday, August 29, 2020
RTT, Drugs, Health, Acetamides, Alkaloids, Colchicine, Polypharmacy, Myocardial infarction, Colcot

Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.

Key Points: 
  • Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.
  • In addition to these meaningful results from COLCOT, colchicine is also being evaluated in the COLCORONA clinical trial.
  • Time-to-treat initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
  • Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT), Eur Heart J Qual Care Clin Outcomes.

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

Retrieved on: 
Saturday, August 29, 2020
RTT, Drugs, Health, Acetamides, Alkaloids, Colchicine, Polypharmacy, Myocardial infarction, Colcot

Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.

Key Points: 
  • Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.
  • In addition to these meaningful results from COLCOT, colchicine is also being evaluated in the COLCORONA clinical trial.
  • Time-to-treat initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
  • Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT), Eur Heart J Qual Care Clin Outcomes.